Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.43

-0.7%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: smh who wrote (28270)	2/18/1999 10:39:00 PM
From: Machaon	Read Replies (1) of 32384

<< There is absolutely no excuse for the lack of clarity in this release. >> I agree. Robinson needs to come out with a better press release. Targretin rights were returned to Ligand along with LGD1268 and LGD1324. Lilly and Ligand were then going to go ahead with second generation RXR agonists. I thought that LGD1268 and LGD1324 WERE the second generation RXR agonists in the LGND/LLY deal!? If so, then what compounds are they going forward with? << The characterization of the release as "vague" is charitable. >> Henry had said today that "At H&Q Robinson indicate that more progress has been made under the LLY alliances than all earlier alliances." It really would be great to find out what Robinson meant by this statement. At the rate of LGND's stock fall lately, I don't think that we shareholders can take much more "progress" in the LLY alliances! <g>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next